Vibativ is a drug owned by Cumberland Pharmaceuticals Inc. It is protected by 11 US drug patents filed in 2013. Out of these, 1 drug patents are active and 10 have expired. Vibativ's patents have been open to challenges since 11 September, 2013. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 01, 2027. Details of Vibativ's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7531623 | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(2 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6635618 | Glycopeptide phosphonate derivatives |
Sep, 2023
(1 year, 1 month ago) |
Expired
|
| US6858584 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(2 years ago) |
Expired
|
| US6872701 | Glycopeptide phosphonate derivatives |
Jun, 2021
(3 years ago) |
Expired
|
| US7008923 | Glycopeptide phosphonate derivatives |
May, 2021
(3 years ago) |
Expired
|
| US7351691 | Glycopeptide phosphonate derivatives |
May, 2021
(3 years ago) |
Expired
|
| US7700550 | Glycopeptide phosphonate derivatives |
May, 2021
(3 years ago) |
Expired
|
| US7208471 | Glycopeptide phosphonate derivatives |
May, 2021
(3 years ago) |
Expired
|
| US7544364 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(3 years ago) |
Expired
|
| US8158580 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(3 years ago) |
Expired
|
| US8101575 | Glycopeptide phosphonate derivatives |
May, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vibativ's patents.
Latest Legal Activities on Vibativ's Patents
Given below is the list of recent legal activities going on the following patents of Vibativ.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 May, 2024 | US8158580 |
| Expire Patent Critical | 26 Feb, 2024 | US8101575 |
| Maintenance Fee Reminder Mailed Critical | 04 Dec, 2023 | US8158580 |
| Maintenance Fee Reminder Mailed Critical | 11 Sep, 2023 | US8101575 |
| Expire Patent Critical | 23 May, 2022 | US7700550 |
| Maintenance Fee Reminder Mailed Critical | 06 Dec, 2021 | US7700550 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2020 | US7544364 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2020 | US7531623 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Oct, 2019 | US8158580 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2019 | US7351691 |
FDA has granted several exclusivities to Vibativ. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vibativ, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vibativ.
Exclusivity Information
Vibativ holds 2 exclusivities. All of its exclusivities have expired in 2016. Details of Vibativ's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
| New Indication(I-673) | Jun 21, 2016 |
US patents provide insights into the exclusivity only within the United States, but Vibativ is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vibativ's family patents as well as insights into ongoing legal events on those patents.
Vibativ's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vibativ's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 01, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vibativ Generics:
There are no approved generic versions for Vibativ as of now.
Alternative Brands for Vibativ
Vibativ which is used for treating bacterial infections, including staphylococcal infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
| Xellia Pharms Aps |
| |||||
About Vibativ
Vibativ is a drug owned by Cumberland Pharmaceuticals Inc. It is used for treating bacterial infections, including staphylococcal infections. Vibativ uses Telavancin Hydrochloride as an active ingredient. Vibativ was launched by Cumberland in 2009.
Approval Date:
Vibativ was approved by FDA for market use on 11 September, 2009.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Vibativ is 11 September, 2009, its NCE-1 date is estimated to be 11 September, 2013.
Active Ingredient:
Vibativ uses Telavancin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Telavancin Hydrochloride ingredient
Treatment:
Vibativ is used for treating bacterial infections, including staphylococcal infections.
Dosage:
Vibativ is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 250MG BASE/VIAL | POWDER | Discontinued | INTRAVENOUS |
| EQ 750MG BASE/VIAL | POWDER | Prescription | INTRAVENOUS |